1. Home
  2. INCY vs TOL Comparison

INCY vs TOL Comparison

Compare INCY & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$117.62

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Logo Toll Brothers Inc.

TOL

Toll Brothers Inc.

HOLD

Current Price

$149.46

Market Cap

15.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCY
TOL
Founded
1991
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
15.1B
IPO Year
1994
1994

Fundamental Metrics

Financial Performance
Metric
INCY
TOL
Price
$117.62
$149.46
Analyst Decision
Buy
Buy
Analyst Count
21
17
Target Price
$103.52
$164.44
AVG Volume (30 Days)
1.5M
836.3K
Earning Date
04-28-2026
05-19-2026
Dividend Yield
N/A
0.72%
EPS Growth
4173.33
N/A
EPS
1.47
4.91
Revenue
$3,394,635,000.00
$7,143,258,000.00
Revenue This Year
$10.44
N/A
Revenue Next Year
$10.99
$6.01
P/E Ratio
$79.38
$29.85
Revenue Growth
13.67
N/A
52 Week Low
$69.70
$117.50
52 Week High
$119.60
$168.36

Technical Indicators

Market Signals
Indicator
INCY
TOL
Relative Strength Index (RSI) 62.08 48.34
Support Level $98.50 $143.40
Resistance Level $119.29 $152.49
Average True Range (ATR) 3.08 4.44
MACD -0.45 -1.02
Stochastic Oscillator 80.75 30.49

Price Performance

Historical Comparison
INCY
TOL

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About TOL Toll Brothers Inc.

Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder within the US according to total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.

Share on Social Networks: